Astra Zeneca
AstraZeneca PLC, a leading global biopharmaceutical company, is headquartered in Cambridge, GB. Founded in 1999 through the merger of Astra AB and Zeneca Group PLC, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in the research, development, and manufacturing of innovative medicines, AstraZeneca focuses on areas such as oncology, cardiovascular, renal, and respiratory diseases. With a commitment to advancing healthcare, AstraZeneca is renowned for its unique portfolio of products, including groundbreaking therapies like Tagrisso and Imfinzi. The company has achieved significant milestones, including rapid vaccine development during the COVID-19 pandemic, solidifying its position as a market leader in the pharmaceutical industry. AstraZeneca continues to drive innovation, aiming to improve patient outcomes worldwide.
DitchCarbon Score
How does Astra Zeneca's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astra Zeneca's score of 94 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astra Zeneca's reported carbon emissions
In 2024, AstraZeneca reported total greenhouse gas emissions of approximately 6,000,000,000 kg CO2e, with significant contributions from Scope 1, 2, and 3 emissions. Specifically, Scope 1 emissions were about 125,386,000 kg CO2e, while Scope 2 emissions amounted to approximately 14,210,000 kg CO2e (market-based) and 217,026,000 kg CO2e (location-based). The majority of emissions, approximately 5,897,822,000 kg CO2e, were classified under Scope 3, highlighting the extensive impact of their supply chain and product use. AstraZeneca has set ambitious climate commitments, aiming for a 98% absolute reduction in Scope 1 and 2 emissions by 2026, using 2015 as the baseline year. Additionally, the company targets a 50% reduction in Scope 3 emissions by 2030, with a long-term goal of achieving a 90% reduction by 2045, based on 2019 levels. Notably, AstraZeneca is committed to sourcing 100% renewable electricity globally by 2025 and transitioning to a fully electric road fleet by the end of 2025. These initiatives are part of AstraZeneca's broader strategy to reach net-zero greenhouse gas emissions across its value chain by 2045, aligning with science-based targets to limit global warming to 1.5°C. The company also aims to ensure that 95% of its suppliers by spend will have science-based targets by 2025, further enhancing its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astra Zeneca is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
